Onyx Biotec

Who are the top shareholders of the Onyx Biotec?

The top shareholders of Onyx Biotec include Naresh Kumar, the largest promoter with 23.97%, four foreign institutional investors holding 5.36%, and Acintyo Investment Fund Pcc- Cell 1 as the highest public shareholder at 4.96%. Individual investors collectively own 18.97% of the shares.

The top shareholders of Onyx Biotec include the promoters, who hold the majority of the shares. Naresh Kumar is the promoter with the highest holding at 23.97%. Additionally, there are four foreign institutional investors (FIIs) that collectively hold 5.36% of the company. The highest public shareholder is Acintyo Investment Fund Pcc- Cell 1, which holds 4.96%. Individual investors collectively own 18.97% of the shares.

When is the next results date for Onyx Biotec?

No Upcoming Board Meetings

Has Onyx Biotec declared dividend?

No Dividend History Available

Who are the peers of the Onyx Biotec?

Onyx Biotec's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, and others. Key insights show excellent management and growth for Sun Pharma, Cipla, and Dr Reddy's Labs, while Onyx Biotec has a 1-year return of 0.00%, lower than its peers.

Peers: The peers of Onyx Biotec are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Biofil Chemicals, Achyut Healthcar, Lasa Supergeneri, Sunil Healthcare, and Godavari Drugs.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Good management risk is found at Divi's Lab., Torrent Pharma, and the rest. Average management risk is noted at Biofil Chemicals and Godavari Drugs, while Below Average management risk is present at Achyut Healthcar, Lasa Supergeneri, and Sunil Healthcare. Growth is Excellent for Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Onyx Biotec, while Below Average growth is seen at Divi's Lab., Torrent Pharma, Biofil Chemicals, Achyut Healthcar, Lasa Supergeneri, and Sunil Healthcare. Average growth is noted at Godavari Drugs. Excellent capital structure is found at Sun Pharma.Inds., Divi's Lab., Cipla, and Dr Reddy's Labs, while Good capital structure is present at Torrent Pharma and Biofil Chemicals, Average at Lasa Supergeneri, and Below Average at Achyut Healthcar, Sunil Healthcare, and Godavari Drugs.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.96%, while Biofil Chemicals has the lowest at -22.04%. Onyx Biotec's 1-year return is 0.00%, which is lower than both. Additionally, the six-month returns for Biofil Chemicals, Achyut Healthcar, Lasa Supergeneri, and Sunil Healthcare are negative.

What is the technical trend for Onyx Biotec?

As of June 2, 2025, Onyx Biotec's trend is neutral and sideways, indicated by lack of clear direction in MACD, Dow Theory, and Bollinger Bands, suggesting a consolidation phase rather than a strong bullish or bearish trend.

As of 2 June 2025, the technical trend for Onyx Biotec has changed from mildly bearish to sideways. The current stance is neutral, reflecting a lack of clear direction. Key indicators supporting this assessment include the MACD showing no signals on both weekly and monthly time frames, and the Dow Theory indicating no trend in either time frame. Additionally, the Bollinger Bands are signaling a sideways movement on the weekly and monthly charts. The stock has recently shown a price increase from the previous close, but overall, the absence of strong momentum indicators suggests a consolidation phase rather than a definitive bullish or bearish trend.

What does Onyx Biotec do?

Onyx Biotec Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, incorporated in 2005 and converted to a Public Limited company in 2024. It currently has no available sales or profit data, with a market cap of INR 90 Cr and a P/E ratio of 18.00.

Overview: <BR>Onyx Biotec Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History: <BR>Onyx Biotec Limited was incorporated in 2005 as `Onyx Biotec Private Limited` and later converted to a Public Limited company, changing its name to `Onyx Biotec Limited` in July 2024. There is no sales or profit data available for the latest quarter.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: N/A <BR>Market-cap value: INR 90 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 18.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.00 <BR>Return on Equity: 0.00% <BR>Price-to-Book: 0.00 <BR><BR>Contact Details: <BR>Address: Not available <BR>Phone: Not available <BR>Email: Not available <BR>Website: Not available

How big is Onyx Biotec?

As of 24th July, Onyx Biotec Ltd has a market capitalization of 90.00 Cr, classifying it as a Micro Cap company. There is no valid data available for recent net sales, net profit, shareholder's funds, or total assets.

As of 24th July, <BR><BR>Market Cap: Onyx Biotec Ltd has a market capitalization of 90.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: There is no valid data available regarding Net Sales or Net Profit for the latest four quarters.<BR><BR>Balance Sheet Snapshot: There is no valid data available for the latest annual period regarding Shareholder's Funds or Total Assets.

Is Onyx Biotec overvalued or undervalued?

As of September 10, 2025, Onyx Biotec is considered undervalued with a valuation grade of very attractive, supported by a PE ratio of 17.67 and favorable comparisons to peers like Sun Pharma and Divi's Lab, despite a year-to-date stock performance lagging at -18.91% compared to the Sensex's 5.62%.

As of 10 September 2025, Onyx Biotec's valuation grade has moved from fair to very attractive, indicating a significant positive shift in its perceived value. The company is currently assessed as undervalued. Key ratios supporting this conclusion include a PE ratio of 17.67, an EV to EBITDA ratio of 8.83, and a ROCE of 12.26%. <BR><BR>In comparison to its peers, Onyx Biotec's valuation metrics stand out favorably; for instance, Sun Pharma has a PE ratio of 33.38, while Divi's Lab is at 69.48, both categorizing them as expensive. This positions Onyx Biotec as a more appealing investment opportunity within the pharmaceuticals and biotechnology sector. Additionally, recent stock performance has lagged behind the Sensex, with a year-to-date return of -18.91% compared to the Sensex's 5.62%, reinforcing the notion that the stock may be undervalued relative to its fundamentals.

How has been the historical performance of Onyx Biotec?

Onyx Biotec has shown consistent growth in net sales and profitability over the past three years, with net sales increasing from 39.48 Cr in Mar'23 to 61.95 Cr in Mar'25, and profit after tax rising from 1.84 Cr to 4.95 Cr during the same period. The company's operating profit margin improved from 11.27% to 16.69%, reflecting strong financial performance.

Answer:<BR>The historical performance of Onyx Biotec shows a consistent growth trajectory in net sales and profitability over the past three fiscal years.<BR><BR>Breakdown:<BR>Onyx Biotec's net sales increased from 39.48 Cr in Mar'23 to 53.75 Cr in Mar'24, and further to 61.95 Cr in Mar'25, indicating a strong upward trend. Total operating income mirrored this growth, reaching 61.95 Cr in Mar'25. The company's total expenditure also rose, from 35.03 Cr in Mar'23 to 51.61 Cr in Mar'25, primarily driven by an increase in raw material costs and employee expenses. Operating profit (PBDIT) improved significantly from 4.58 Cr in Mar'23 to 11.51 Cr in Mar'25, with a corresponding increase in the operating profit margin from 11.27% to 16.69%. Profit before tax followed suit, rising from 2.55 Cr in Mar'23 to 6.48 Cr in Mar'25, while profit after tax also saw a substantial increase from 1.84 Cr to 4.95 Cr during the same period. The earnings per share (EPS) grew from 1.56 in Mar'23 to 3.72 in Mar'25, reflecting enhanced shareholder value. On the balance sheet, total assets increased from 74.14 Cr in Mar'24 to 91.25 Cr in Mar'25, with total liabilities rising from 74.14 Cr to 91.25 Cr, primarily due to a reduction in long-term borrowings. Cash flow from operating activities remained stable, contributing to a net cash inflow of 7.00 Cr in Mar'25, up from 1.00 Cr in Mar'24. Overall, Onyx Biotec has demonstrated robust growth in sales, profits, and cash flow, positioning itself favorably in the market.

Why is Onyx Biotec Ltd falling/rising?

As of 11-Feb, Onyx Biotec Ltd's stock price is at 35.50, showing a 1.43% increase due to strong investor participation and relative outperformance in its sector, despite longer-term declines. The stock's current position above the 20-day and 50-day moving averages suggests a potential short-term positive trend.

As of 11-Feb, Onyx Biotec Ltd's stock price is rising, currently at 35.50, reflecting a change of 0.5 or 1.43% increase. This upward movement can be attributed to several factors. Firstly, the stock has outperformed its sector by 0.6% today, indicating a relative strength compared to its peers. Additionally, there has been a significant increase in investor participation, with a delivery volume of 32,000 shares on 10 February, which represents a remarkable rise of 788.89% against the 5-day average delivery volume. <BR><BR>Moreover, while the stock is currently lower than its 5-day, 100-day, and 200-day moving averages, it is higher than the 20-day and 50-day moving averages, suggesting a potential short-term positive trend. Despite the stock's poor performance over longer periods, such as a 48.51% decline over the past year, the recent trading activity and relative outperformance today indicate a momentary rise in investor confidence.

Which are the latest news on Onyx Biotec?